The reference price range for Vebreltinib Enteric-Coated Capsules is approximately US$$865 to U$$1,730 per box (30-capsule pack). The exact cost varies based on factors such as drug specifications, region, medical insurance policies, and purchasing channels, and shall be subject to the actual price at the dispensing institution. As a prescription drug, it must be evaluated by a qualified medical professional prior to use and administered strictly in accordance with prescribing instructions.
Key Factors Affecting Pricing
Indication & Specifications
Vebreltinib is primarily indicated for the treatment of non-small cell lung cancer (NSCLC) harboring specific genetic mutations (e.g., MET exon 14 skipping mutation). Prices vary substantially across different specifications (e.g., dosage strength, number of capsules per pack).
Region & Purchasing Channel
Prices at tertiary hospitals in first-tier cities or large pharmacies may be higher than those in second- and third-tier cities. Patient out-of-pocket costs are reduced if the drug is covered by medical insurance at designated healthcare facilities.
Medical Insurance & Preferential Policies
The drug may be partially covered by basic medical insurance or local supplementary insurance schemes in some regions; patients are advised to prepare diagnostic certificates and other required documents for reimbursement applications. Individual pharmaceutical companies or charitable organizations may offer patient assistance programs (PAPs) to further alleviate financial burdens.
Important Precautions
Prescription Compliance
Vebreltinib is available only with a valid medical prescription. Do not adjust the dosage or discontinue treatment without medical supervision, as this may increase the risk of drug resistance or exacerbate adverse reactions.
Adverse Reaction Management
Common side effects include edema, fatigue, nausea, etc. Routine monitoring of hepatic and renal function is required during treatment. Seek immediate medical attention if severe adverse events occur (e.g., dyspnea, persistent high fever).
Long-Term Follow-Up
Radiological imaging and blood tests are recommended every 3 months during treatment to evaluate therapeutic efficacy and facilitate timely regimen adjustments.
For the most up-to-date pricing information or medication support services, please consult the pharmacy of a formal medical institution or contact your local medical insurance authority to inquire about reimbursement details.
